Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025

Contributed by: Business Wire

Logo

Images

Business Wire associated0

Business Wire embedded0

Tags

Science

Radiology

Biotechnology

Research

Oncology

General Health

Health

Genetics

BluePrint

More Like This

Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays

Personalized biology-based insights (Graphic: Business Wire)

Agendia, Inc. Provides Review of Successful 2024

(Graphic: Business Wire)

Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit

(Graphic: Business Wire)

MammaPrint® Reimbursement Indication Extended in Belgium

Groundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer

PR Newswire associated0

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®